Physician profile
Erica Catterall Sharp
NPI 1467431684
$1,277.77
in general payments reported to CMS, 2019-2025
14 companies · $356 in 2025
The $356 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.75 · 2020: $52.39 · 2021: $85.32 · 2022: $94.15 · 2023: $408 · 2024: $210 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $180.90 | 2023-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $170.95 | 2019-2025 | Doc Band |
| Biomarin Pharmaceutical INC. | $142.84 | 2025 | Voxzogo 1.2mg |
| Sanofi Pasteur INC. | $142.77 | 2020-2023 | |
| Corium, LLC | $136.37 | 2023-2024 | Azstarys, Azstarys |
| Tris Pharma INC | $134.68 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $125.75 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $74.71 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $49.71 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $32.27 | 2024 | Bexsero |
| Ironshore Pharmaceuticals INC. | $24.65 | 2024 | |
| Verrica Pharmaceuticals INC. | $22.27 | 2024 | Ycanth |
| Collegium Pharmaceutical, INC. | $21.13 | 2025 | Jornay Pm |
| Seqirus USA INC | $18.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.